You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Protein Qspec: An Improved Method for Rapid Characterization of Protein Aggregates in Biologic Drugs for Increased Quality and Safety

    SBC: OPTOFLUIDICS, INC.            Topic: 90201

    Optofluidics will develop Protein Qspec, a new particle analysis QC instrument designed to characterize protein aggregates in biologic drugs. The primary concern for this class of therapeutics is that they can elicit an immune response from patients who develop anti-drug antibodies which can eliminate the therapeutic benefit. The presence of particulate matter, in these therapeutics (e.g. shed gla ...

    SBIR Phase I 2016 Department of CommerceNational Institute of Standards and Technology
  2. I Corps Program for A rapid instrument free diagnostic assay for the early detection and quantification of sepsis biomarkers in blood

    SBC: ACCEL DIAGNOSTICS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The objective of this proposed SBIR Phase I is to complete the proof of principle of a novel blood based biomarker assay for the diagnosis and management of Sepsis pScreen Sep tm pScreen Sep tm has several unique features It is fully disposable single use and does not requires external electronic equipment i e benchtop or handheld devices hence it ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection

    SBC: Lynthera Corporation            Topic: N

    DESCRIPTION provided by applicant This project intends to create a contact lens for ocular drug delivery that resolves key barriers to commercial feasibility Contact lens drug delivery has been studied for many years but technical challenges such as constant rate release and controlled triggering have inhibited progress Current prototypes release drugs at a decreasing rate and undesirably b ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Portable Transdermal Acoustic Patch for Delivery of Large Molecules to Improve HIV Patient Medication Regime Compliance by Elimination of Side Effects Including Injection Site Reactions

    SBC: ACTUATED MEDICAL, INC.            Topic: R

    DESCRIPTION provided by applicant This Phase IIB SBIR finalizes development conducts in depth preclinical testing and completes Verification and Validation of the Portable Transdermal Acoustic Patch TAP for Delivery of Large Molecules to Improve HIV Patient Medication Regime Compliance by Elimination of Side Effects Including Injection Site Reactions Nearly million people worldwide are ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Malarial Retinopathy Screening System for Improved Diagnosis of Cerebral Malaria

    SBC: VisionQuest Biomedical Inc            Topic: NIAID

    DESCRIPTION provided by applicant Cerebral malaria CM is a life threatening neurological complication associated with malarial infection Malaria affects about million people worldwide and claims lives annually of whom are African children under years of age CM is mistakenly over diagnosed about of the time in which the cases of concurrent non CM diseases with simil ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Chemical Optimization of a novel class of USP inhibitor for cancer treatment

    SBC: Progenra, Inc            Topic: 102

    DESCRIPTION provided by applicant Numerous regulatory proteins are tightly controlled by ubiquitin conjugation and deconjugation and deviations from this dynamic process are manifested in clinical disorders such as cancer inflammation neurodegenerative disorders and metabolic diseases The deubiquitylase DUB USP plays multiple regulatory roles all of which are pro survival antiapoptotic ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Prevention Economic Impact Model PEIM

    SBC: Mosaix Software, Inc.            Topic: R

    DESCRIPTION provided by applicant The proposed Fast Track SBIR grant application is for the creation of a Web based Interactive Prevention Economic Impact Model PEIM which enables substance abuse prevention organizations to select cost effective evidence based interventions for specific target populations and estimate the economic impact of prevention using service delivery data and ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Low Insertion Force Epidural Actuated Needle System for Enhanced Control and Tactile Feel During Epidural Insertion

    SBC: ACTUATED MEDICAL, INC.            Topic: 300

    DESCRIPTION provided by applicant In this NIH Phase IIB Competing Renewal SBIR project Actuated Medical Inc will finalize and clinically test the andquot Low Insertion Force Epidural LIFE Actuated Needle Insertion System for Enhanced Control and Tactile Feel andquot LIFE uses closed loop control of a vibrating needle to provide the clinician a more controlled entry through tough muscle a ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Integrated In Vitro and Alternative Ocular IIVAO Irritation Testing Strategy

    SBC: MB RESEARCH LABORATORIES, INC.            Topic: N

    DESCRIPTION provided by applicant Ocular irritation testing is extremely relevant to assuring adequate safety levels of public health as new formulations of chemicals and products are introduced In most cases these safety assessments are performed using the Draize Rabbit Eye test resulting in thousands of rabbits used in testing every year Alternatives have been discussed since the s with ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. A Phase a clinical trial of ALK in geographic atrophy

    SBC: ALKEUS PHARMACEUTICALS, INC.            Topic: NEI

    DESCRIPTION provided by applicant The long term goal of this work is to develop an oral drug for the prevention of age related macular degeneration AMD AMD is the leading cause of blindness in the United States with million Americans diagnosed or at risk of irreversibly losing vision and over million people who already have debilitating vision loss Currently there is no FDA approved ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government